Idraparinux - Investigational Agent for the Treatment and Prevention of Thromboembolic Events

Print

VTE is the third most common cardiovascular disease after heart attack and stroke. (Source: ABPI)
 
Next»

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development